# Three Ways Into the Same GH Pulse

> Compare Sermorelin, Tesamorelin, and Ipamorelin — bigtimepeptides — A side-by-side comparison of three Growth Hormone Axis research peptides — sermorelin, tesamorelin, and ipamorelin — across receptor mechanism, evidence maturity, regulatory status, and key caution.

**GROWTH HORMONE AXIS / MATRIX**

How sermorelin, tesamorelin, and ipamorelin differ in mechanism, evidence maturity, regulatory status, and what each is actually studied for.

## The short version

This page lines up sermorelin, tesamorelin, and ipamorelin on the dimensions that matter most when reading GH-axis peptide research: receptor mechanism, evidence maturity, regulatory status, and the single biggest caution for each. The short version: all three eventually produce the same downstream event — a pulse of growth hormone release from the pituitary — but they reach it through two different receptors, and they sit at very different points on the evidence ladder. Tesamorelin is the only one with an active FDA approval and the deepest trial record. Sermorelin has a real, if older, human trial record and a history of prior approval. Ipamorelin has the thinnest confirmed human evidence — one Phase 2 trial that didn't hit its primary endpoint — despite being widely discussed in research communities. None of this is medical advice, and no dose is recommended here for any individual.

## The comparison matrix

| Dimension | Sermorelin | Tesamorelin | Ipamorelin |
| --- | --- | --- | --- |
| Receptor mechanism | GHRH receptor agonist (natural 1-29 fragment) | GHRH receptor agonist (stabilized 44-aa analogue) | Ghrelin receptor (GHS-R1a) agonist |
| Most-studied in | Pediatric GH deficiency (historical); sleep, recovery, body composition (community use) | HIV-associated lipodystrophy (visceral fat) | Postoperative bowel recovery (single RCT); GH pulse pharmacokinetics |
| Evidence base | Multiple human trials, decades old; pediatric growth data, cognition trial (as a class), editorial commentary [1][2][3][4][5] | Multiple RCTs, a 2026 meta-analysis, 52-week extension data, LiverTox safety monograph [6][7][8][9][10][11][12] | One Phase 2 human RCT (missed endpoint), one human PK study, preclinical/animal data only otherwise [13][14][15][16][17] |
| Regulatory status | Previously FDA-approved (Geref, NDA 020443); withdrawn 2008 for commercial reasons; compounded today | FDA-approved (NDA 022505, 2010) for HIV-associated lipodystrophy only | Never approved anywhere; sold as a research chemical |
| Key caution | Long-term anti-aging benefit unproven; gray-market product-quality concerns | Off-label use outside HIV lipodystrophy is investigational; benefit reverses on discontinuation | Thin confirmed human safety data; class-level cardiotoxicity signal from a related compound, not ipamorelin itself |

## Receptor mechanism

Sermorelin and tesamorelin both work through the GHRH receptor — sermorelin is a natural 29-amino-acid fragment of GHRH itself, while tesamorelin is the full 44-amino-acid molecule with a chemical modification that extends its stability in the bloodstream. Ipamorelin works through a different receptor entirely — the ghrelin / growth hormone secretagogue receptor (GHS-R1a) — which happens to trigger the same downstream GH pulse through a separate signaling path. That mechanistic split is exactly why ipamorelin is so often studied and dosed alongside a GHRH analog like sermorelin or tesamorelin rather than substituted for one: the two mechanisms are additive rather than redundant.

## Evidence maturity

This is where the three genuinely separate. Tesamorelin has by far the deepest evidence base of the three: a 2026 meta-analysis pooling five RCTs, a pivotal 26-week Phase 3 trial that led to its approval, a 52-week extension, a dedicated JAMA trial, and an NIH LiverTox safety monograph [6][7][8][10][11]. Sermorelin's human trial record is older but real — pediatric growth-velocity data from the 1990s, plus a placebo-controlled cognition trial in older adults (though that trial actually dosed tesamorelin, and is cited on sermorelin's page because it's the best-controlled data for a GHRH analog's cognitive effect) [2][5]. Ipamorelin has the thinnest confirmed human record of the three: one Phase 2 RCT that missed its primary endpoint, one small acute pharmacokinetic study, and otherwise animal and in vitro data [15][16].

## Regulatory status

Tesamorelin is the only one of the three with an active FDA approval, and it's a narrow one — reducing excess abdominal fat in HIV-associated lipodystrophy, nothing broader. Sermorelin was FDA-approved decades ago under the brand name Geref for pediatric growth hormone deficiency, then withdrawn from the market in 2008 for commercial reasons, not safety or efficacy failures; it's available today mainly through compounding pharmacies as a Category 1 bulk drug substance under FDA's interim 503A policy. Ipamorelin has never been approved by any regulator for any indication and is sold strictly as a research chemical; in 2024 it was also removed from Category 2 of the interim 503A bulk-substances list, which restricts compounding-pharmacy access further.

## Key caution

Each compound carries a defining caveat. For sermorelin, it's that strong anti-aging and wellness marketing claims outrun the evidence, and much of the product sold outside the regulated pharmacy channel comes from an unregulated, sometimes mislabeled or contaminated market [3]. For tesamorelin, it's that the approval is narrow — off-label use is investigational, and the visceral-fat benefit reverses within weeks of stopping the drug [10]. For ipamorelin, it's the combination of a thin confirmed human safety record and a class-level cardiotoxicity signal seen in a chronic dosing study of a related — not identical — ghrelin-receptor agonist, which keeps its long-term cardiovascular profile genuinely uncharacterized [14].

---

bigtimepeptides is an independent research digest on the growth-hormone axis — not a pharmacy, not a clinic, and not a source for any of the compounds it writes about.